{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Healthy Returns","title":"1.1 Stewart Bartlett | Ferronova ","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/1b465bcc\"></iframe>","width":"100%","height":180,"duration":580,"description":"Improving Cancer Surgery with Ferronova's Precision ImagingIn this episode of Healthy Returns, we sit down with Stewart Bartlett, CEO of Ferronova, to explore how innovative imaging technology is transforming cancer surgery. Stewart shares insights into how Ferronova's nanoparticle-based approach can improve patient outcomes, reduce overtreatment, and potentially save lives.\nKey Topics:The unmet needs in oesophageal and stomach cancer treatmentHow Ferronova's iron oxide nanoparticle technology works during surgeryThe significance of lymph node mapping in cancer metastasisResults from clinical trials with 100% accuracy in identifying targeted lymph nodesRegulatory roadmap in Australia and Europe, expecting approval in 3-4 yearsMarket potential driven by healthcare economics, with treatment recurrence costs reaching $430,000 in the USCompetitive landscape and comparison to radiopharmaceutical diagnosticsTimestamps:\n00:00 - Introduction and episode overview\n00:27 - Stewart Bartlett's background in engineering and medtech\n01:05 - Ferronova's focus on precision imaging for cancer surgery\n01:44 - The origin of Ferronova from university research\n02:11 - Unmet needs in oesophageal and stomach cancer treatments\n02:52 - The nanoparticle technology for lymph node mapping\n03:48 - Overcoming challenges of chemotherapy and radiotherapy\n04:11 - MRI visibility and magnetic detector during surgery\n04:54 - Surgical application of Ferronova's device\n05:16 - How the system targets and drains lymph nodes\n05:45 - Clinical trial progress and accuracy results\n06:23 - Next steps and timeline for regulatory approval\n06:58 - Estimated timeframe of three to four years for market readiness\n07:49 - Market potential and economic benefits of reducing recurrence costs\n08:23 - Comparison with radiopharmaceutical diagnostics\n09:02 - Final thoughts and closing Resources & Links:Ferronova Official WebsiteIron Oxide Nanoparticles ExplainedClinical Trials Data --ENDS--","thumbnail_url":"https://img.transistorcdn.com/hEylySeSIZrWjm7H4mHabBqMDtgWlTpMVK97xlEHsQ4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85N2Q0/ZTJiZjdhYmZhMTAw/MDc1YjdmNjk0MDg0/YjczZC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}